Multiple ascending doses of recombinant human lecithin-cholesterol acyltransferase in patients with atherosclerosis: phase 2a primary results

被引：0
|
作者：
Bonaca, M. [1 ]
George, R. T. [2 ]
Morrow, D. A. [1 ]
Abuhsira, L. [2 ]
She, D. [2 ]
Park, J. G. [1 ]
Hirshberg, B. [2 ]
Sabatine, M. [1 ]
机构：
[1] Brigham & Womens Hosp, Med, Cardiol, Vasc Med, 75 Francis St, Boston, MA 02115 USA
[2] MedImmune, Gaithersburg, MD USA
来源：
EUROPEAN HEART JOURNAL | 2018年 / 39卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
354
引用
收藏
页码：49 / 50
页数：2
相关论文
共 50 条
  • [21] Recombinant human lecithin-cholesterol acyltransferase Fc fusion: Analysis of N- and O-linked glycans and identification and elimination of a xylose-based O-linked tetrasaccharide core in the linker region
    Spahr, Chris
    Kim, Justin J.
    Deng, Sihong
    Kodama, Paul
    Xia, Zhen
    Tang, Jay
    Zhang, Richard
    Siu, Sophia
    Nuanmanee, Noi
    Estes, Bram
    Stevens, Jennitte
    Zhou, Mingyue
    Lu, Hsieng S.
    PROTEIN SCIENCE, 2013, 22 (12) : 1739 - 1753
  • [22] Evaluation of potential antiplatelet effects of CSL112 (Apolipoprotein A-I [Human]) in patients with atherosclerosis: results from a phase 2a study
    Paul A. Gurbel
    Udaya S. Tantry
    Denise D’Andrea
    Thomas Chung
    John H. Alexander
    Kevin P. Bliden
    Samuel D. Wright
    Pierluigi Tricoci
    Journal of Thrombosis and Thrombolysis, 2018, 45 : 469 - 476
  • [23] Evaluation of potential antiplatelet effects of CSL112 (Apolipoprotein A-I [Human]) in patients with atherosclerosis: results from a phase 2a study
    Gurbel, Paul A.
    Tantry, Udaya S.
    D'Andrea, Denise
    Chung, Thomas
    Alexander, John H.
    Bliden, Kevin P.
    Wright, Samuel D.
    Tricoci, Pierluigi
    JOURNAL OF THROMBOSIS AND THROMBOLYSIS, 2018, 45 (04) : 469 - 476
  • [24] Randomized, Placebo-Controlled Phase 2b Study to Evaluate the Safety and Efficacy of Recombinant Human Lecithin Cholesterol Acyltransferase in Acute ST-Segment-Elevation Myocardial Infarction: Results of REAL-TIMI 63B
    Bonaca, Marc P.
    Morrow, David A.
    Bergmark, Brian A.
    Berg, David D.
    Lima, Joao A. C.
    Hoffmann, Udo
    Kato, Yoko
    Lu, Michael T.
    Kuder, Julia
    Murphy, Sabina A.
    Spinar, Jindrich
    Ophuis, Ton Oude
    Kiss, Robert G.
    Lopez-Sendon, Jose
    Averkov, Oleg
    Wheatcroft, Stephen B.
    Kubica, Jacek
    Nicolau, Jose Carlos
    Furtado, Remo H. M.
    Abuhatzira, Liron
    Hirshberg, Boaz
    Omar, Sami A.
    Vavere, Andrea L.
    Chang, Yi-Ting
    George, Richard T.
    Sabatine, Marc S.
    CIRCULATION, 2022, 146 (12) : 907 - 916
  • [25] Cytokine profile following multiple ascending doses of recombinant human interleukin-12 (rhIL-12) subcutaneously administered to patients with chronic hepatitis C infection
    O'Brien, CB
    Henzel, BS
    Moonka, DK
    HEPATOLOGY, 1998, 28 (04) : 274A - 274A
  • [26] Safety, tolerability, and pharmacokinetics of single- and multiple-ascending doses of olamkicept: Results from randomized, placebo-controlled, first-in-human phase I trials
    Wagner, Frank-Dietrich
    Schreiber, Stefan
    Bagger, Yu
    Bruzelius, Katharina
    Falahati, Ali
    Sternebring, Ola
    Ravi, Arjun
    Pinton, Philippe
    CTS-CLINICAL AND TRANSLATIONAL SCIENCE, 2024, 17 (05):
  • [27] A phase II study of recombinant human interferon-(alpha 2a) and zidovudine in patients with AIDS-related Kaposi's sarcoma
    Fischl, MA
    Finkelstein, DM
    He, WL
    Powderly, WG
    Triozzi, PL
    Steigbigel, RT
    Maiewski, S
    Dale, E
    Millar, L
    Gould, M
    Ratner, L
    Para, MF
    Gower, R
    Tenzler, R
    Fuhrer, J
    Mildvan, D
    Malamud, SC
    Dezube, B
    Chapman, B
    Crumpacker, C
    Israel, HB
    Feinberg, J
    Hood, A
    Raines, CP
    Miles, SA
    Mitsuyasu, RT
    Carden, J
    McMahon, D
    Pazin, G
    Schulof, RS
    Cortless, JL
    leLacheur, SF
    Ehmann, WC
    Eyster, ME
    McKinley, GF
    Grieco, MH
    Kolatch, B
    Bennett, JM
    Rybak, ME
    Cheeseman, SH
    Koup, RA
    Diamond, A
    JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES AND HUMAN RETROVIROLOGY, 1996, 11 (04): : 379 - 384
  • [28] Controlled release recombinant human interferon-α2b for treating patients with chronic hepatitis C genotype 1: a phase 2a clinical trial
    Dzyublyk, I.
    Yegorova, T.
    Moroz, L.
    Popovych, O.
    Zaytsev, I.
    Miroshnichenko, V.
    Kromminga, A.
    Wilkes, M. M.
    van Hoogdalem, E. J.
    Humphries, J. E.
    JOURNAL OF VIRAL HEPATITIS, 2011, 18 (04) : 271 - 279
  • [29] Infusion of Reconstituted High-Density Lipoprotein, CSL112, in Patients With Atherosclerosis: Safety and Pharmacokinetic Results From a Phase 2a Randomized Clinical Trial
    Tricoci, Pierluigi
    D'Andrea, Denise M.
    Gurbel, Paul A.
    Yao, Zhenling
    Cuchel, Marina
    Winston, Brion
    Schott, Robert
    Weiss, Robert
    Blazing, Michael A.
    Cannon, Louis
    Bailey, Alison
    Angiolillo, Dominick J.
    Gille, Andreas
    Shear, Charles L.
    Wright, Samuel D.
    Alexander, John H.
    JOURNAL OF THE AMERICAN HEART ASSOCIATION, 2015, 4 (08): : e002171
  • [30] Phase 2 multiple ascending-dose study of SRP-5051 PPMO in patients with DMD amenable to exon 51 skipping: Part A results
    Campbell, Craig
    Mathews, Katherine
    van de Rijn, Marc
    Palatinsky, Emanuel
    Ni, Xiao
    Sha, Nanshi
    Sehinovych, Ihor
    Tinsley, Jon
    Malhotra, Jyoti
    O'Rourke, Erin
    Phan, Han
    GENETICS IN MEDICINE, 2022, 24 (03) : S133 - S133
12345